title: The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure.
abstract: Some pathogens (e.g., Mycobacterium tuberculosis, Toxoplasma gondii, Leishmania spp) have been shown to persist in their host after clinical cure, establishing the risk of disease reactivation. We analyzed the conditions necessary for the long term maintenance of Leishmania major in genetically resistant C57BL/6 mice after spontaneous healing of their dermal lesions. Interleukin (IL)-10 was found to play an essential role in parasite persistence as sterile cure was achieved in IL-10-deficient and IL-4/IL-10 double-deficient mice. The requirement for IL-10 in establishing latency associated with natural infection was confirmed in IL-10-deficient mice challenged by bite of infected sand flies. The host-parasite equilibrium was maintained by CD4+ and CD8+ T cells which were each able to release IL-10 or interferon (IFN)-gamma, and were found to accumulate in chronic sites of infection, including the skin and draining lymph node. A high frequency of the dermal CD4+ T cells released both IL-10 and IFN-gamma. Wild-type mice treated transiently during the chronic phase with anti-IL-10 receptor antibodies achieved sterile cure, suggesting a novel therapeutic approach to eliminate latency, infection reservoirs, and the risk of reactivation disease.
authors.affiliation: Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg. 4 Rm. 126, Center Dr. MSC 0425, Bethesda, MD 20892, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Belkaid
authors.forename: K F
authors.initials: KF
authors.lastname: Hoffmann
authors.forename: S
authors.initials: S
authors.lastname: Mendez
authors.forename: S
authors.initials: S
authors.lastname: Kamhawi
authors.forename: M C
authors.initials: MC
authors.lastname: Udey
authors.forename: T A
authors.initials: TA
authors.lastname: Wynn
authors.forename: D L
authors.initials: DL
authors.lastname: Sacks
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D007371:Interferon-gamma / Q000502:physiology; D016753:Interleukin-10 / Q000502:physiology*; D015847:Interleukin-4 / Q000502:physiology; D018320:Leishmania major / Q000502:physiology*; D016773:Leishmaniasis, Cutaneous / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D018123:Receptors, Interleukin / Q000037:antagonists & inhibitors*; D053701:Receptors, Interleukin-10; D012867:Skin / Q000276:immunology / Q000469:parasitology*
chemical_list: D000911:Antibodies, Monoclonal; D018123:Receptors, Interleukin; D053701:Receptors, Interleukin-10; D016753:Interleukin-10; D015847:Interleukin-4; D007371:Interferon-gamma